Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
Assoumou L, Cozzi-Lepri A, Brun-Vézinet F, Degruttola V, Kuritzkes DR, Phillips A, Zolopa A, Miller V, Flandre P, Costagliola D; Standardization, Clinical Relevance of HIV Drug Resistance Testing Project from the Forum for Collaborative HIV Research. Assoumou L, et al. AIDS. 2010 Jan 28;24(3):365-71. doi: 10.1097/QAD.0b013e32833338ba. AIDS. 2010. PMID: 19864933
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martínez E; NEAT 022 Study Group. Sempere A, et al. Among authors: assoumou l. Clin Infect Dis. 2023 Oct 5;77(7):991-1009. doi: 10.1093/cid/ciad297. Clin Infect Dis. 2023. PMID: 37207617
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. González-Cordón A, et al. Among authors: assoumou l. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. J Antimicrob Chemother. 2023. PMID: 37539492
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.
Costagliola D, Descamps D, Assoumou L, Morand-Joubert L, Marcelin AG, Brodard V, Delaugerre C, Mackiewicz V, Ruffault A, Izopet J, Plantier JC, Tamalet C, Yerly S, Saidi S, Brun-Vezinet F, Masquelier B; Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS) AC11 Resistance Study Group. Costagliola D, et al. Among authors: assoumou l. J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):12-8. doi: 10.1097/QAI.0b013e318074eb73. J Acquir Immune Defic Syndr. 2007. PMID: 17514016
HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
Soulié C, Marcelin AG, Ghosn J, Amellal B, Assoumou L, Lambert S, Duvivier C, Costagliola D, Katlama C, Calvez V. Soulié C, et al. Among authors: assoumou l. AIDS. 2007 Oct 18;21(16):2243-5. doi: 10.1097/QAD.0b013e3282f0e3d0. AIDS. 2007. PMID: 18090053
HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.
Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group. Descamps D, et al. Among authors: assoumou l. J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13. J Antimicrob Chemother. 2008. PMID: 18552344
Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452).
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C; ORVACS Study Group. Autran B, et al. Among authors: assoumou l. AIDS. 2008 Jul 11;22(11):1313-22. doi: 10.1097/QAD.0b013e3282fdce94. AIDS. 2008. PMID: 18580611 Clinical Trial.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.
Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research. Assoumou L, et al. J Infect Dis. 2008 Aug 15;198(4):470-80. doi: 10.1086/590156. J Infect Dis. 2008. PMID: 18598191
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group. Duvivier C, et al. Among authors: assoumou l. J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18. J Antimicrob Chemother. 2008. PMID: 18641035 Clinical Trial.
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D; ANRS 121 Hippocampe study group. Duvivier C, et al. Among authors: assoumou l. AIDS. 2009 Apr 27;23(7):817-24. doi: 10.1097/QAD.0b013e328328f789. AIDS. 2009. PMID: 19363330 Clinical Trial.
121 results